NanoVibronix, Inc. - Common Stock (NAOV)
Frequently Asked Questions About NanoVibronix, Inc. - Common Stock (NAOV)
Has NanoVibronix conducted clinical trials?
Yes, NanoVibronix has conducted clinical trials for its products to validate their safety and efficacy. These trials are essential in demonstrating the benefits of their technology, ensuring regulatory compliance, and supporting product claims for healthcare professionals and patients.
How can customers purchase NanoVibronix products?
Customers can purchase NanoVibronix products through healthcare providers, hospitals, and online platforms. The company often collaborates with distributors to facilitate product availability in various regions, making it accessible to healthcare professionals and their patients.
How does NanoVibronix ensure product quality?
NanoVibronix ensures product quality through strict adherence to regulatory standards and quality management systems. The company conducts rigorous testing and quality control processes throughout the product development cycle to maintain high standards for safety and effectiveness.
How does NanoVibronix's technology work?
NanoVibronix's ultrasound technology works by emitting low-frequency sound waves that penetrate the tissue, promoting healing and pain relief. The ultrasound waves stimulate cellular activity, enhance blood flow, and accelerate the natural healing process, providing patients with a non-invasive treatment option.
Is NanoVibronix involved in any partnerships?
Yes, NanoVibronix actively seeks partnerships with hospitals, research institutions, and other companies to enhance its technology and increase its market reach. Collaborating with external organizations enables the company to leverage shared expertise and resources to foster innovation.
Is NanoVibronix publicly traded?
Yes, NanoVibronix, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol NAOV. As a publicly-traded company, it is subject to various regulatory requirements and disclosures.
What are competitors of NanoVibronix?
NanoVibronix competes with other medical device companies that develop non-invasive therapeutic solutions, including those that use ultrasound technology. Competitors may also include companies focusing on pain management and infection prevention devices, such as traditional pain relief products and catheter solutions.
What are the benefits of NanoVibronix's products?
The benefits of NanoVibronix's products include non-invasive treatment options, minimal side effects, ease of use, and the ability to improve patient outcomes. By utilizing ultrasound technology, these products offer effective solutions for pain management and wound healing without surgical intervention.
What are the future plans for NanoVibronix?
NanoVibronix plans to continue expanding its product line and applications, focusing on research and development to innovate new solutions in ultrasound therapy. The company also aims to strengthen its market presence through strategic partnerships and increased marketing efforts to reach more healthcare providers and patients.
What clinical applications does NanoVibronix focus on?
NanoVibronix primarily focuses on pain management and infection prevention as its clinical applications. The company's products are designed to relieve pain, enhance recovery, and introduce alternative therapeutic methods that minimize the reliance on drugs.
What does NanoVibronix, Inc. do?
NanoVibronix, Inc. is a medical device company focused on the development and commercialization of therapeutic ultrasound-based products. The company aims to enhance patient outcomes through innovative non-invasive solutions that can be used in various medical fields, including pain management and wound healing.
What is NanoVibronix's approach to innovation?
NanoVibronix focuses on cutting-edge research and innovation to create new products that address unmet medical needs. The company's approach combines advanced technology with a strong understanding of clinical challenges, aiming to develop solutions that improve patient care.
What is NanoVibronix's market strategy?
NanoVibronix's market strategy involves targeting niche segments within the healthcare market, establishing collaboration with key opinion leaders, and leveraging partnerships with other medical device companies, healthcare institutions, and distribution networks to expand its product reach.
What is NanoVibronix's primary technology?
The primary technology developed by NanoVibronix is the use of low-frequency ultrasound for therapeutic applications. This technology facilitates pain relief and promotes healing, utilizing non-invasive methods that enhance the efficacy of therapies without the need for pharmacological interventions.
What is the mission of NanoVibronix?
The mission of NanoVibronix is to develop innovative, non-invasive medical solutions that improve patient outcomes. The company's goal is to harness the power of ultrasound technology to provide effective therapeutic options that significantly enhance quality of life for patients.
What products does NanoVibronix offer?
NanoVibronix offers several products, including PainShield and UroShield. PainShield is designed for pain management, providing non-invasive relief through ultrasound technology, while UroShield is aimed at preventing catheter-associated urinary tract infections through its innovative ultrasound application.
What regulatory approvals has NanoVibronix received?
NanoVibronix has received regulatory approvals for its products from various agencies, including the U.S. Food and Drug Administration (FDA). These approvals are crucial for bringing its products to market and ensuring they meet the safety and efficacy requirements for healthcare use.
When was NanoVibronix, Inc. founded?
NanoVibronix, Inc. was founded in 2008. Since its inception, the company has worked diligently to develop its proprietary technology and bring its unique ultrasound solutions to the healthcare market.
Where is NanoVibronix headquartered?
NanoVibronix, Inc. is headquartered in Elmsford, New York. This strategic location allows the company to be near important healthcare hubs and access to markets and resources necessary for development and distribution.
Who are NanoVibronix's target customers?
The target customers for NanoVibronix include healthcare providers, hospitals, and patients seeking effective, non-invasive therapeutic options. The company also reaches out to specialty clinics that focus on pain management, wound care, and urology.
What is the current price of NanoVibronix, Inc. - Common Stock?
The current price of NanoVibronix, Inc. - Common Stock is 2.320
When was NanoVibronix, Inc. - Common Stock last traded?
The last trade of NanoVibronix, Inc. - Common Stock was at 3:59 pm EDT on April 3rd, 2025
What is the market capitalization of NanoVibronix, Inc. - Common Stock?
The market capitalization of NanoVibronix, Inc. - Common Stock is 1.76M
How many shares of NanoVibronix, Inc. - Common Stock are outstanding?
NanoVibronix, Inc. - Common Stock has 759.30K shares outstanding.